Casper Pharma gets 2 USFDA observations
Maharashtra: Suven Pharma has announced that the United States Food & Drug Administration (US FDA) has completed the surveillance inspection of Casper Pharma Private Limited in Hyderabad, a WOS of the company with two observations.
The inspection took place from July 8, 2024, to July 12, 2024.
"The Company has been issued a Form 483 with two observations, which are procedural in nature. We are committed to addressing these observations within the stipulated timeline," Suven Pharma stated.
An FDA Form 483 is issued to firm management at the conclusion of an inspection when an investigator(s) has observed any conditions that in their judgment may constitute violations of the Food Drug and Cosmetic (FD&C) Act and related Acts.
Read also: Suven Pharma to buy 67.5 percent stake in Sapala Organics for Rs 229.5 crore
Disclaimer: This website is primarily for healthcare professionals. The content here does not replace medical advice and should not be used as medical, diagnostic, endorsement, treatment, or prescription advice. Medical science evolves rapidly, and we strive to keep our information current. If you find any discrepancies, please contact us at corrections@medicaldialogues.in. Read our Correction Policy here. Nothing here should be used as a substitute for medical advice, diagnosis, or treatment. We do not endorse any healthcare advice that contradicts a physician's guidance. Use of this site is subject to our Terms of Use, Privacy Policy, and Advertisement Policy. For more details, read our Full Disclaimer here.
NOTE: Join us in combating medical misinformation. If you encounter a questionable health, medical, or medical education claim, email us at factcheck@medicaldialogues.in for evaluation.